American Journal of Epidemiology Advance Access published online on April 26, 2006
American Journal of Epidemiology, doi:10.1093/aje/kwj125
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Yale Center for Perinatal, Pediatric and Environmental Epidemiology, Yale University, New Haven, CT
* To whom correspondence should be addressed. Studies investigating antenatal caffeine consumption and reproductive outcomes show conflicting results, and most studies have used maternal self-reported caffeine consumption to estimate fetal exposure. This study (n = 1,606) was specifically designed to test the association of caffeine and its primary metabolites in umbilical cord blood with intrauterine growth restriction (IUGR). Pregnant women were recruited from 56 obstetric practices and 15 clinics affiliated with six hospitals in Connecticut and Massachusetts between September 1996 and January 2000. In an adjusted model including caffeine only, levels in all quartiles were associated with reduced risk of IUGR. In adjusted analyses including paraxanthine and caffeine, serum paraxanthine levels in the highest quartile were associated with increased risk of IUGR (adjusted odds ratio = 3.29, 95% confidence interval: 1.17, 9.22); caffeine remained protective. These conflicting findings suggest that cytochrome P-450 1A2 (CYP1A2) metabolic activity may be associated with IUGR, so the ratio of paraxanthine to caffeine was then modeled. The likelihood of IUGR increased 21% for every one standard deviation change in the ratio (adjusted odds ratio = 1.21, 95% confidence interval: 1.07, 1.37), suggesting that CYP1A2 activity, and not the absolute levels of paraxanthine, influences fetal growth. No associations were observed between caffeine or any metabolites and preterm delivery.
Received September 14, 2005
Accepted December 22, 2005
ORIGINAL CONTRIBUTIONS
Caffeine Metabolites in Umbilical Cord Blood, Cytochrome P-450 1A2 Activity, and Intrauterine Growth Restriction
Laura M. Grosso 1 *,
Elizabeth W. Triche 1,
Kathleen Belanger 1,
Neal L. Benowitz 2,
Theodore R. Holford 1,
and
Michael B. Bracken 1
2 Division of Clinical Pharmacology and Experimental Therapeutics at the University of California, San Francisco, San Francisco, CA
Laura M. Grosso, E-mail: laura.grosso{at}yale.edu
Abstract 
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  N. Momoi, J. P. Tinney, L. J. Liu, H. Elshershari, P. J. Hoffmann, J. C. Ralphe, B. B. Keller, and K. Tobita Modest maternal caffeine exposure affects developing embryonic cardiovascular function and growth Am J Physiol Heart Circ Physiol, May 1, 2008; 294(5): H2248 - H2256. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Xue, W. C. Willett, B. A. Rosner, M. R. Forman, and K. B. Michels Parental characteristics as predictors of birthweight Hum. Reprod., January 1, 2008; 23(1): 168 - 177. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Tomimatsu, S. J. Lee, J. Pereyra Pena, J. M. Ross, J. A. Lang, and L. D. Longo Maternal Caffeine Administration and Cerebral Oxygenation in Near-Term Fetal Sheep Reproductive Sciences, September 1, 2007; 14(6): 588 - 594. [Abstract] [PDF]
|
|
|
|
 |
|
 B. H. Bech, C. Obel, T. B. Henriksen, and J. Olsen Effect of reducing caffeine intake on birth weight and length of gestation: randomised controlled trial BMJ, February 24, 2007; 334(7590): 409 - 409. [Abstract] [Full Text] [PDF]
|
|